Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Xencor Inc (XNCR)
NASDAQ:XNCR
Holding XNCR?
Track your performance easily
XNCR Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$16.49 - $26.84
Previous Close$19.71
Volume405.98K
Average Volume (3M)618.46K
Market Cap
$1.22B
Enterprise Value$768.42M
Total Cash (Recent Filing)$535.94M
Total Debt (Recent Filing)$89.33M
Price to Earnings (P/E)―
Beta1.08
Next Earnings
Jul 31, 2024EPS Estimate
-$0.82Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.19
Shares Outstanding61,662,550
10 Day Avg. Volume698,003
30 Day Avg. Volume618,463
Standard Deviation0.12
R-Squared0.14
Alpha-0.00815
Financial Highlights & Ratios
Price to Book (P/B)1.82
Price to Sales (P/S)95.35
Price to Cash Flow (P/CF)1.70
P/FCF Ratio1.60
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.74
Enterprise Value/Gross Profit4.57
Enterprise Value/Ebitda-7.08
Forecast
1Y Price Target
$35.56Price Target Upside80.69% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
Xencor News
PremiumCompany Announcements
Xencor Reports Q3 2024 Earnings and Program Updates
PremiumPre-Earnings
Is XNCR a Buy, Before Earnings?
PremiumCompany Announcements
Xencor Board Member Dagmar Rosa-Bjorkeson to Step Down
Bulls Say, Bears Say
Bulls Say
Clinical ProgramsThe first patient was recently dosed in XmAb541's Ph1 dose escalation study.
Financial PositionThe company is well-positioned to execute on its long-term strategy with an experienced management team and strong financial position.
Pipeline ProgressRecent pipeline progress included FDA approval of Ultomiris in neuromyelitis optica spectrum disorder, which uses XNCR's Xtend technology.
Bears Say
Financial ImpactRemoving plamotamab royalties from financial models has lowered the target price from $34 to $32.
Market CompetitionCompetitive dynamics with CD20 in NHL suggest that resources might be better allocated to other projects.
Partnership TerminationJNJ's termination of its rights to plamotamab could signal challenges in the drug's potential success.
---
Ownership Overview
25.19% Insiders
44.64% Mutual Funds
28.25% Other Institutional Investors
1.93% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
XNCR FAQ
What was Xencor Inc’s price range in the past 12 months?
Xencor Inc lowest stock price was $16.49 and its highest was $26.84 in the past 12 months.
What is Xencor Inc’s market cap?
Currently, no data Available
When is Xencor Inc’s upcoming earnings report date?
Xencor Inc’s upcoming earnings report date is Jul 31, 2024 which is 118 days ago.
How were Xencor Inc’s earnings last quarter?
Xencor Inc released its earnings results on May 09, 2024. The company reported -$1.11 earnings per share for the quarter, missing the consensus estimate of -$0.83 by -$0.28.
Is Xencor Inc overvalued?
According to Wall Street analysts Xencor Inc’s price is currently Undervalued.
Does Xencor Inc pay dividends?
Xencor Inc does not currently pay dividends.
What is Xencor Inc’s EPS estimate?
Xencor Inc’s EPS estimate is -$0.82.
How many shares outstanding does Xencor Inc have?
Xencor Inc has 61,662,550 shares outstanding.
What happened to Xencor Inc’s price movement after its last earnings report?
Xencor Inc reported an EPS of -$1.11 in its last earnings report, missing expectations of -$0.83. Following the earnings report the stock price went down -4.503%.
Which hedge fund is a major shareholder of Xencor Inc?
Among the largest hedge funds holding Xencor Inc’s share is PRIMECAP Management Co. It holds Xencor Inc’s shares valued at 201M.
---
Xencor Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$35.56 (80.69% Upside)
$35.56 (80.69% Upside)
Blogger Sentiment
Bullish
XNCR Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 507.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $111.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 5.1%
Last 30 Days ▼ 5.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-16.14%
12-Months-Change
Fundamentals
Return on Equity
-20.58%
Trailing 12-Months
Asset Growth
10.06%
Trailing 12-Months
Company Description
Xencor Inc
Xencor, Inc. engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Monrovia, CA.
---
XNCR Earnings Call
Q4 2024
0:00 / 0:00
---
XNCR Stock 12 Month Forecast
Average Price Target
$35.56
▲(80.69% Upside)
Technical Analysis
Best Analysts Covering XNCR
1 Year
1 Year Success Rate
6/9 ratings generated profit
1 Year Average Return
+7.01%
reiterated a sell rating 7 months ago
Copying Peter Lawson's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +7.01% per trade.
---